Opportunity Information: Apply for RFA AG 20 029
The National Institutes of Health (NIH) funding opportunity titled "Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required)" (Funding Opportunity Number RFA-AG-20-029; CFDA 93.866) supports research that tests practical, real-world clinical strategies for treating people who have Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD) along with other common co-occurring medical conditions. The central goal is to improve the effectiveness of treatment approaches for these comorbid conditions in patients with AD/ADRD, using pragmatic clinical trials designed to fit routine care settings and produce results that can be implemented broadly.
This announcement uses an R61/R33 phased award structure and requires a clinical trial. In general terms, the R61 phase is intended to support early, milestone-driven work that sets up the pragmatic trial and demonstrates readiness to proceed, while the R33 phase supports the larger-scale execution of the trial once predefined milestones are met. The emphasis on pragmatic trials signals a focus on interventions that can work under typical clinical conditions, often leveraging existing health systems, care pathways, and data sources, rather than highly controlled efficacy studies that may be difficult to translate into everyday practice.
A key theme of the opportunity is multimorbidity, meaning the presence of multiple chronic conditions at the same time. In the AD/ADRD population, managing additional illnesses can be especially challenging because cognitive impairment affects medication adherence, symptom reporting, care coordination, and decision-making. This FOA is aimed at generating evidence on better ways to manage frequently co-occurring conditions alongside dementia care, with the intent of improving outcomes that matter in real-world contexts, such as patient functioning, safety, quality of life, caregiver burden, health care utilization, and the overall effectiveness of care strategies when dementia is part of the clinical picture.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
At the same time, there are clear limits on foreign participation. Non-domestic (non-U.S.) entities and non-domestic foreign institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed, which means an otherwise eligible U.S. applicant may be able to include certain foreign activities or collaborations when they meet NIH policy definitions and requirements.
The opportunity is categorized as a discretionary grant under the NIH, with the original posting created on May 9, 2019, and an original closing date of February 3, 2020. The source information provided does not specify an award ceiling or the expected number of awards. Overall, the FOA is best understood as NIH support for studies that can produce usable, practice-relevant evidence on how to manage common combinations of dementia and other chronic health problems, using pragmatic clinical trial methods and a phased approach intended to de-risk and strengthen the transition from planning to full implementation.Apply for RFA AG 20 029
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2019-05-09.
- Applicants must submit their applications by 2020-02-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AG-20-029.
What is the CFDA number listed for this opportunity?
The CFDA number provided is 93.866.
What is the overall purpose of this FOA?
This FOA supports research that tests practical, real-world clinical strategies for treating people with Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD) who also have other common co-occurring medical conditions. The intent is to improve how these comorbid conditions are treated when dementia is part of the clinical picture, using pragmatic clinical trials in routine care settings so results can be implemented broadly.
What kind of study design does NIH emphasize here?
The FOA emphasizes pragmatic clinical trials. That generally means studies designed to fit within typical clinical conditions (routine care), often leveraging existing health systems, care pathways, and data sources, rather than highly controlled efficacy studies that may be harder to translate into everyday practice.
Is a clinical trial required?
Yes. The announcement explicitly states "Clinical Trial Required."
What does "multimorbidity" mean in the context of this opportunity?
Multimorbidity refers to the presence of multiple chronic conditions at the same time. In this FOA, the focus is on people with AD/ADRD who also have other common co-occurring medical conditions, and on finding better ways to manage those conditions alongside dementia care.
Why is managing co-occurring conditions especially challenging for people with AD/ADRD?
The FOA notes that cognitive impairment can make management of other illnesses more difficult by affecting medication adherence, symptom reporting, care coordination, and decision-making.
What outcomes does this FOA aim to improve?
The FOA highlights real-world outcomes such as patient functioning, safety, quality of life, caregiver burden, health care utilization, and the overall effectiveness of care strategies when dementia is part of the clinical picture.
What award mechanism is used?
This FOA uses an R61/R33 phased award structure.
What is the R61 phase intended to support?
The R61 phase is intended to support early, milestone-driven work that sets up the pragmatic trial and demonstrates readiness to proceed to the larger trial phase.
What is the R33 phase intended to support?
The R33 phase supports the larger-scale execution of the pragmatic clinical trial once predefined milestones are met.
How does the phased R61/R33 structure relate to project readiness?
Based on the description provided, the phased approach is designed so that early work in the R61 phase establishes the trial and demonstrates readiness, and only then does the project move into the R33 phase for full trial execution after meeting milestones.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and governmental entities, including:
- State, county, city, or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Native American tribal organizations that are not federally recognized
- Public housing authorities and Indian housing authorities
- Nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories)
- For-profit organizations (other than small businesses)
- Small businesses
Are any additional institution types explicitly highlighted as eligible?
Yes. The FOA explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Are non-U.S. (foreign) organizations eligible to apply as the applicant?
No. Non-domestic (non-U.S.) entities and non-domestic foreign institutions are not eligible to apply.
Can a U.S. organization include non-domestic components in its application?
No. The information provided states that non-domestic components of U.S. organizations are not eligible to apply.
Are any foreign activities allowed at all?
Yes. The FOA indicates that foreign components (as defined in the NIH Grants Policy Statement) are allowed. This suggests an otherwise eligible U.S. applicant may be able to include certain foreign activities or collaborations when they meet NIH policy definitions and requirements.
What federal agency is offering this funding opportunity?
The opportunity is offered through the National Institutes of Health (NIH).
What type of grant is this considered?
It is categorized as a discretionary grant under the NIH.
When was the opportunity originally posted?
The original posting date provided is May 9, 2019.
What was the original closing date?
The original closing date provided is February 3, 2020.
Does the provided information list an award ceiling or expected number of awards?
No. The source information provided does not specify an award ceiling or the expected number of awards.
What makes this FOA "pragmatic" rather than a traditional efficacy study?
Based on the description provided, pragmatic trials are meant to work under typical clinical conditions and often use existing health systems, routine care pathways, and existing data sources, with the goal of producing findings that can be implemented broadly in everyday practice.
What kinds of research projects are a good fit for this FOA (at a high level)?
Projects that test practical, real-world strategies for managing common co-occurring medical conditions in people with AD/ADRD, using a pragmatic clinical trial design, and that can demonstrate readiness through milestones (R61) before proceeding to full trial execution (R33).
Browse more opportunities from the same category: Health
Next opportunity: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)
Previous opportunity: Cooperative Watersheds Studies Program: Shenandoah Watershed Study (SWAS) and the Virginia Trout Stream Sensitivity Study (VTSSS)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 20 029
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 20 029) also looked into and applied for these:
| Funding Opportunity |
|---|
| Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed) Apply for RFA NS 19 019 Funding Number: RFA NS 19 019 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance Apply for GH BAA 2018 ADDENDUM02 Funding Number: GH BAA 2018 ADDENDUM02 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 19 281 Funding Number: PAR 19 281 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed) Apply for RFA RM 19 004 Funding Number: RFA RM 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Innovations in Malaria Vaccine Development (IMV) Apply for GH BAA 2018 ADDENDUM03 Funding Number: GH BAA 2018 ADDENDUM03 Agency: Agency for International Development Category: Health Funding Amount: $35,500,000 |
| Postdoctoral Research Associate Training (PRAT) Program (Fi2) Apply for PAR 19 286 Funding Number: PAR 19 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed) Apply for RFA TR 19 020 Funding Number: RFA TR 19 020 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Enhanced Diversity Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 19 014 Funding Number: RFA HG 19 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges Apply for CA NAV 19 001 Funding Number: CA NAV 19 001 Agency: CMS-Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) Apply for RFA HG 19 015 Funding Number: RFA HG 19 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed) Apply for PAR 19 288 Funding Number: PAR 19 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 025 Funding Number: RFA AG 20 025 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 19 289 Funding Number: PAR 19 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Adolescent Health and Well-Being in Urban Areas Apply for BAA NIGERIA HPNIAH 2019 Funding Number: BAA NIGERIA HPNIAH 2019 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed) Apply for RFA AI 19 042 Funding Number: RFA AI 19 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 043 Funding Number: RFA AI 19 043 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Oscillatory Patterns of Gene Expression in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 040 Funding Number: RFA AG 20 040 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Exploratory Grant for NIA Alzheimers Disease Research Center (P20 Clinical Trial Not Allowed) Apply for RFA AG 20 023 Funding Number: RFA AG 20 023 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed) Apply for RFA HL 20 007 Funding Number: RFA HL 20 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Interpersonal Processes in Alzheimer's Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional) Apply for RFA AG 20 006 Funding Number: RFA AG 20 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 20 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.